ロード中...

Novel ligands that target the mitochondrial membrane protein mitoNEET

Ligands of the thiazolidinedione (TZD) class of compounds, pioglitazone (Actos™) and rosiglitazone (Avandia™) are currently approved for treatment of type 2 diabetes and are known to bind to the PPAR-γ nuclear receptor subtype. Recent evidence suggesting PPAR-γ independent action of the TZDs led to...

詳細記述

保存先:
書誌詳細
主要な著者: Bieganski, Robert M., Yarmush, Martin L.
フォーマット: Artigo
言語:Inglês
出版事項: 2011
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3477874/
https://ncbi.nlm.nih.gov/pubmed/21531159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jmgm.2011.04.001
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!